Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ho Sze, Chan"'
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-13 (2019)
Abstract Background Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no dedicated monograph
Externí odkaz:
https://doaj.org/article/141e9329f65147aa821d8049aea5c156
Autor:
Daniel A. Pryma, John M. Maris, Robert H. Mach, Bruce R. Pawel, Roger A. Greenberg, Sean D. Carlin, Kuiying Xu, Daniel Martinez, Pichai Raman, Catherine Hou, Ho Sze Chan, Chi-Chang Weng, Komal S. Rathi, Sean W. Reilly, Laura N. Puentes, Hwan Lee, Mehran Makvandi
SI Figure 1: Reaction scheme for synthesizing 1-(4-astatophenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one ([211At]MM4) from tin precursor 1-(4-(tributylstannyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; SI Figure 2: Reverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119714469e6f6f337985a31a1b82ffd9
https://doi.org/10.1158/1535-7163.22506018
https://doi.org/10.1158/1535-7163.22506018
Autor:
Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong, Wouter A. P. Breeman
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-15 (2016)
Abstract Background 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing le
Externí odkaz:
https://doaj.org/article/d7180907a14a49deaffb973b6e210c3c
Autor:
Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181473 (2017)
BACKGROUND:Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emissi
Externí odkaz:
https://doaj.org/article/39e34314c1ef4c309f082c3494f4fd68
Autor:
Ho Sze Chan1 h.s.chan1982@gmail.com, de Blois, Erik1, Konijnenberg, Mark W.1, Morgenstern, Alfred2, Bruchertseifer, Frank2, Norenberg, Jeffrey P.3, Verzijlbergen, Fred J.1, de Jong, Marion1, Breeman, Wouter A. P.1
Publikováno v:
EJNMMI Radiopharmacy & Chemistry. 5/14/2016, p1-15. 15p.
Autor:
Mehran Makvandi, Hwan Lee, Robert H. Mach, John M. Maris, Daniel Martinez, Pichai Raman, Roger A. Greenberg, Kuiying Xu, Chi-Chang Weng, Catherine Hou, Sean D. Carlin, Sean W. Reilly, Ho Sze Chan, Laura N. Puentes, Komal S. Rathi, Daniel A. Pryma, Bruce R. Pawel
Publikováno v:
Mol Cancer Ther
Alpha-emitters can be pharmacologically delivered for irradiation of single cancer cells, but cellular lethality could be further enhanced by targeting alpha-emitters directly to the nucleus. PARP-1 is a druggable protein in the nucleus that is overe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e75e9114da8d8ff6f2f78abc8bd2443
https://doi.org/10.1158/1535-7163.mct-18-0837
https://doi.org/10.1158/1535-7163.mct-18-0837
Publikováno v:
Journal of Radioanalytical and Nuclear Chemistry-Articles, 321(1), 285-291. Springer Netherlands
[177Lu]Lu-DOTA-PSMA-617 for PRRT is subject to radiolysis and therefore loses receptor affinity. This will be detrimental for treatment efficacy. In this study optimal quencher(s) (combinations) are determined to maintain radiochemical purity with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aafad9d5865cbda766743b257e1e97f
https://doi.org/10.1007/s10967-019-06573-y
https://doi.org/10.1007/s10967-019-06573-y
Publikováno v:
Nuclear Medicine and Biology, 64-65, 16-21. Elsevier Inc.
Introduction 68Ga-radiopharmaceuticals are common in the field of Nuclear Medicine to visualize receptor-mediated processes. In contrast to straightforward labeling procedures for clinical applications, preclinical in vitro and in vivo applications a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdfc334c0c15839c6e959cd1a1bf8b03
https://pure.eur.nl/en/publications/b613a1a0-ba92-43ea-aeda-d18573d7f4f3
https://pure.eur.nl/en/publications/b613a1a0-ba92-43ea-aeda-d18573d7f4f3
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, 4(1). Springer Science+Business Media
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-13 (2019)
EJNMMI Radiopharmacy and Chemistry
EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-13 (2019)
EJNMMI Radiopharmacy and Chemistry
Background Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no dedicated monograph within th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740a7e05f0a358049f4a19950874bd56
https://pure.eur.nl/en/publications/f4b41bf1-edbe-4a69-a5ed-07f7a07d9333
https://pure.eur.nl/en/publications/f4b41bf1-edbe-4a69-a5ed-07f7a07d9333
Autor:
Wouter A.P. Breeman, Jeffrey P. Norenberg, Alfred Morgenstern, Frank Bruchertseifer, Fred J. Verzijlbergen, Erik de Blois, Ho Sze Chan, Marion de Jong, Mark Konijnenberg
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-15 (2016)
Ejnmmi Radiopharmacy and Chemistry
Ejnmmi Radiopharmacy and Chemistry
Background 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing less than 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f7f8ff8caf2f7f18490cd1c8baa3de3
http://link.springer.com/article/10.1186/s41181-016-0014-4
http://link.springer.com/article/10.1186/s41181-016-0014-4